Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Recombinant Human VEGF Receptors binding domains Fc fragment Region (human IgG1) Protein

Catalog No.: YR0066

Basic Information

Molecular Weight
115 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

What is research grade Aflibercept biosimilar? Research grade Aflibercept biosimilar has the same amino acid sequence as Aflibercept (trade name Eylea), a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). It inhibits vascular endothelial growth factor (VEGF), and is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Aflibercept is a dimeric glycoprotein with a molecular weight of 96.9 kilo Daltons (kDa). Glycosylation adds its molecular weight to 115 kDa in total. Ziv-aflibercept (trade name Zaltrap) was developed as an injection for treatment of metastatic colorectal cancer.

Reported Applications

Functional assays,and those a ssays for studying biological pathways affected by afliberce pt.

Immunogen Information

Clone
Aflibercept Biosimilar

Isotype
Human IgG1 Fc

Immunogen
/

RecommendedIsotype Control(s)
In Vivo Grade Recombinant Human IgG1 Fc Protein

Recommended Dilution Buffer
1×PBS pH 6.1

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

Product Information

Production
Purified from cell culture supernatant in an animal-free facility

Purification
Protein A or G purification

Storage
Store at -20℃